AI pioneer Innoplexus and phytopharmaceutical company DrD are partnering toRead More
Partnering to unlock the true potential of cannabis in medical care
Innoplexus has been accepted to NVIDIA Inception Program
Innoplexus will now be a part of NVIDIA Inception Program. A program that is designed to nurture dedicated and exceptional startups who are revolutionizing industries with advances in AI and data science. The Inception Program helps during different stages of product development, prototyping, and deployment.
The formal confirmation came on May 23rd, 2018. It all started when our Co-founder and CTO, Gaurav Tripathi explained about Innoplexus, our products and what we are doing in Deep Learning to Inception program coordinators at GPU Technology Conference in San Francisco. The program owners liked our idea, especially the way we are using Deep Learning to revolutionize the pharmaceutical industry.
After receiving the confirmation of this virtual accelerator program, Gaurav said, “I have been a huge NVIDIA fan from my gaming days (once upon a time in history, I do used to play) and my PC assembling days (used to sell assembled PCs in IITB campus for some quick money). I have seen it grow from a ‘graphic card’ company to the AI giant that it is now and have been looking for a chance to do something with them or get associated in some way.”
Innoplexus will now get a custom set of ongoing benefits like access to NVIDIA global network and the Deep Learning Institute as well as GPU hardware discounts,and early access to state-of-the-art technology. “This is a very supportive opportunity on our way to an European Artificial Intelligence-Champion”, summarizes Gaurav.
The original article was published on NVIDIA.
Featured News
Partex and Singapore’s Experimental Drug Development Centre collaborate to bring
Frankfurt, Germany, 3rd June 2024, 9am CET Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to…
Partex Partners with Lupin to Revolutionize Drug Discovery through AI-Driven
Frankfurt, Germany, 23 April 2024 – Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to…
Partex NV announces collaboration with Althea DRF Lifesciences to provide
Frankfurt, Germany; 28 March 2024 – Partex Group, a pioneer in AI-driven drug discovery, announces a collaboration with Althea DRF…
Innovative AI technology in oncology: Partex Group presents results from
During the German Cancer Congress 2024 in Berlin, the companies Innoplexus AG /Amrit AG, companies of Partex N.V., presented the…
Partex NV Forges Collaboration with Sanofi in AI-Based Dossier Enrichment
Frankfurt, Germany; 14 March 2024 Partex Group, a pioneer in AI-driven drug discovery, today announces a collaboration with global pharmaceutical…
Innoplexus and AIO Studien gGmbH are jointly announcing the start
January 02, 2024 – Innoplexus and Amrit AG, members of the Partex NV Group, providers of innovative technology for health…
Strategic partnership announcement: Innoplexus holding company Partex NV is pleased
Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience. Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to announce…
AI supports targeted therapy recommendations fortumor diseases – BMBF funds
The treatment and support of patients with advanced tumor diseases is a complex task involving numerous disciplines. For the interdisciplinary…
Innoplexus and Innovatrix capital partner to bring about new risk-transfer
Artificial Intelligence (AI) pioneer Innoplexus and London based Parametric Insurance start-up, Innovatrix Capital, collaborating upon using AI & Machine Learning…
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial Intelligence to expedite PIM kinase inhibitor development ESCHBORN, Germany, May 30,…
